Global Hemostasis Diagnostics Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers

This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the hemostasis diagnostics market during this decade.

The report explores business and technological trends in world’s seven major markets; provides estimates of the test volume, instrument placements and installed base, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.

Rationale

The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromagenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, computers and laboratory automation will radically change the hemostasis diagnostics practice during the next ten years.

New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Hemostasis testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the hemostasis testing closer to the patient, thus creating additional opportunities and challenges for suppliers.

Geographic Coverage

• France
• Germany
• Italy
• Japan
• Spain
• UK
• USA

• Sales and market shares of major instrument and reagent suppliers.

• Extensive strategic profiles of major suppliers and emerging market entrants.

• Comprehensive market segmentation analysis, including:
  • Hospitals
  • Commercial/Private Laboratories
  • Physician Offices
  • Ambulatory Care Clinics.
• The 2010, 2015 and 2020 test forecasts for 40 major procedures, by country and market segment.

• Review of over 40 established and new procedures.
• Comparison of over 50 automated and semi-automated analyzers from Diagnostica Stago, Helena, IL, Siemens, Sysmex, Trinity Biotech and other suppliers.

• Analysis of current and emerging technologies and their potential market applicants.
• Comprehensive lists of companies developing or marketing new technologies and products by test.

• Estimates of facilities performing hemostasis diagnostic tests, by country.
• Test volume and sales projections by country.

• Product development and business expansion opportunities with significant market appeal.
• “Ideal” product models with tentative prices and operating characteristics.
• Alternative market penetration strategies for instrument and reagent suppliers.
• Potential market entry barriers and risks.

The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products in the U.S., five major European countries and Japan.

In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, and Venture Planning Group’s proprietary data files was conducted.